Abbreviations
- PPD:
-
Purified protein derivative
- TNF:
-
Tumor necrosis factor
References
Blumberg HM, Burman WJ, Chaisson RE et al (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 67:603–62
Kalaajieh WK (1999) Epidemiology of tuberculosis in Lebanon. Int J Tuberc Lung Dis 3:774–777
Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104
Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122–2127
Hamilton CD (2003) Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum 48:2085–2091
Targeted tuberculin testing and treatment of latent tuberculosis infection (2000) This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 161(4 Pt 2):S221–247
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Uthman, I., Kanj, N., El-Sayad, J. et al. Miliary tuberculosis after infliximab therapy in Lebanon. Clin Rheumatol 23, 279–280 (2004). https://doi.org/10.1007/s10067-004-0873-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-004-0873-z